Hikma Pharmaceutical | HIK - Cost Of Sales


Hikma Pharmaceutical reported $959M in Cost of Sales for its fiscal semester ending in December of 2025.





Cost Of Sales Change Date
Almirall EUR 191.5M 2.29M Dec/2025
argenx SE USD 121M 28.69M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Autolus Therapeutics Ltd USD 24.57M 762K Mar/2026
Bayer EUR 5.23B 731M Mar/2026
Fresenius EUR 4.45B 262M Dec/2025
Genmab DKK 81M 23M Dec/2025
GlaxoSmithKline GBP 1.88B 736M Mar/2026
GRIFOLS EUR 1.08B 214.82M Mar/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Lakefront Biotherapeutics EUR 4.8M 4.34M Mar/2026
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.07B 219M Mar/2026
Orion EUR 163.7M 22.9M Mar/2026
Recordati EUR 202.6M 13.03M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
UCB EUR 1.07B 146M Dec/2025